Abstract:With the continuous popularization of smart medicine, the protective effect of silibinin in the liver has attracted much attention. This study mainly explores the liver protection mechanism and absorption promotion technology of silybin based on intelligent medical analysis. Refining of silibinin: accurately weigh 1.0 g of silibinin in a three-necked flask; gradually add 50 mL of anhydrous methanol, reflux and filter the precipitated solid; and weigh it after drying. ICR male mice were taken as experimental subjects and randomly divided into groups of 10 each. The mice in the normal group and the model group were given intragastrically with 0.5% CMC-Na solution; the mice in the silibinin group were given intragastrically with SB/CMC-Na suspension; the mice in the remaining groups were given low, medium, and high-dose suspensions to their stomachs, and silibinin 23 acylate/CMC-Na suspension was administered at a dose of 10 mL/kg for 7 consecutive days. After that, the mice were fasted for 12 hours. After 6 hours of fasting (18 hours after modeling), the blood cells from their orbits were taken, placed in a 37°C water bath for 30 minutes, and centrifuged at 4000 rpm for 10 minutes, and then the serum was taken; the activity equivalent of AST and ALT in serum was measured; serum determination Medium AST and ALT vitality. The mice were killed by decapitation, fresh liver tissue was immediately collected, and part of it was frozen in liquid nitrogen for the RT-PCR test. The hepatocyte expansion and death were observed using a transmission electron microscope, and the oncosis index (OI) was calculated. Another part of the liver tissue was fixed in 4% paraformaldehyde solution, embedded in paraffin, dehydrated, and sliced at 4 μm. Some sections were stained with conventional HE, and the pathological changes of liver cells were observed under light microscope; some sections were subjected to immunohistochemistry. Only one mouse died when 240 mg/kg of silibinin was given 10 minutes after the model was modeled. However, when 240 mg/kg silibinin was given to the mice 20 minutes after modeling, the mortality rate of the mice rose to 50%, and the therapeutic effect was significantly weakened. This research is helpful to advance the research of silybin in liver protection.

Effect of Silybin on High-Fat-induced Fatty Liver in Rats.

Effect of Silybin Meglumine Tablets on Treatment of Nonalcoholic Steatohepatitis in Rats

The Influence of Silybin-Phospholipid Complex Treatment on Fatty Liver Disease and Atherosclerosis in Rats Fed with High-Fat Diet

Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α

Silymarin alleviates hepatic oxidative stress and protects against metabolic disorders in high-fat diet-fed mice.

Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells

The comparison of the effects of nano-silymarin and silymarin on high-fat diet-induced fatty liver of adult male rats

Silibinin Capsules Improves High Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Hamsters Through Modifying Hepatic De Novo Lipogenesis and Fatty Acid Oxidation

Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease

Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats

Silymarin protects against renal injury through normalization of lipid metabolism and mitochondrial biogenesis in high fat-fed mice

Mechanism-Based Inhibitory and Peroxisome Proliferator-Activated Receptor Α–dependent Modulating Effects of Silybin on Principal Hepatic Drug-Metabolizing Enzymes

Silybum Marianum Oil Attenuates Hepatic Steatosis and Oxidative Stress in High Fat Diet-Fed Mice.

Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity Via Activation of Farnesyl X Receptor.

Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice

[Protective effect of silibinin on islet β cells in C57BL/6J mice fed a highfat diet]

Silibinin Ameliorates Hepatic Lipid Accumulation and Oxidative Stress in Mice with Non-Alcoholic Steatohepatitis by Regulating CFLAR-JNK Pathway

Liver Protection Mechanism and Absorption Promotion Technology of Silybin Based on Intelligent Medical Analysis

Silymarin ameliorates palmitic acid induced insulin resistance and its mechanism

Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

Exercise-activated hepatic autophagy combined with silymarin is associated with suppression of apoptosis in rats subjected to dexamethasone induced- fatty liver damage